The Packard Center for ALS Research (Packard ALS Research Center) at the [University of Pennsylvania](/institutions/university-pennsylvania) is one of the world's leading translational research centers dedicated to understanding and treating amyotrophic lateral sclerosis (ALS). Established in 2001 with a landmark gift from the Packard family, the center has been instrumental in advancing ALS therapeutics.
Overview
The Packard Center represents a unique model for ALS research, bridging the gap between basic science and clinical application. The center brings together researchers from diverse disciplines including neuroscience, genetics, pharmacology, and bioengineering to tackle ALS from multiple angles[@packarda].
History
The center was founded through a transformative $11.5 million gift from the Packard family—James Packard and his wife Elise—whose commitment to ALS research was motivated by family members affected by the disease. This investment created one of the first dedicated ALS research centers in the United States[@packard].
Key Milestones
- 2001: Packard Center founded with $11.5M gift
- 2004: ALS tissue bank established
- 2011: [TDP-43](/mechanisms/tdp-43-proteinopathy) discovery published
- 2016: [C9orf72](/entities/c9orf72) research program launched
- 2020: New drug screening facility opened
Research Focus
Gene Discovery and Mechanism
The center has been a leader in identifying genetic causes of ALS[@packarda]:
- Discovery of [TDP-43](/proteins/tdp-43-protein) as the major protein in ALS inclusions (2006)
- Research on [FUS](/genes/fus) gene mutations
- [C9orf72](/genes/c9orf72) repeat expansion studies
- Investigation of novel genetic risk factors
Therapeutic Development
The Packard Center focuses on developing new treatments through[@packard]:
- Drug screening programs
- Antisense oligonucleotide development
- Viral gene therapy approaches
- Stem cell models for drug testing
- Biomarker discovery
Clinical Research
The center's clinical research program includes[@packarda]:
- Biomarker development studies
- Clinical trials for new therapeutics
- Natural history studies
- Patient registry and tissue banking
Key Programs
ALS Center of Excellence
The clinical arm provides comprehensive care through a multidisciplinary clinic offering[@packarda]:
- Neurology consultations
- Respiratory care
- Nutritional support
- Physical and occupational therapy
- Clinical trial access
ALS Tissue Bank
One of the largest ALS tissue banks in the world, providing researchers worldwide with post-mortem tissue for research[@packard].
Drug Screening Program
The center operates high-throughput drug screening to identify compounds that[@packarda]:
- Protect motor [neurons](/entities/neurons)
- Reduce toxic protein aggregates
- Modulate immune responses
- Enhance mitochondrial function
Notable Discoveries
Packard Center researchers have made several landmark discoveries[@packard]:
TDP-43 pathology (2006) - Identified TDP-43 as the defining protein in ALS inclusions
C9orf72 mechanism - Characterized toxic gain-of-function from repeat expansions
SOD1 models - Developed improved mouse models for therapeutic testing
Biomarkers - Identified [neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain as a progression markerRelated Pages
- [ALS](/diseases/amyotrophic-lateral-sclerosis)
- [TDP-43](/proteins/tdp-43-protein)
- [C9orf72](/genes/c9orf72)
- [University of Pennsylvania](/institutions/university-pennsylvania)
- [ALS Treatments](/therapeutics/als-platform-trial)
Future Directions
The Packard Center continues to pursue innovative research directions. Current focus areas include[@packard]:
- Gene therapy: Developing AAV-based treatments to deliver protective genes to motor neurons
- Combination therapies: Testing synergistic approaches targeting multiple disease pathways
- Personalized medicine: Using patient-derived stem cells to screen for optimal treatments
- Digital health: Implementing remote monitoring tools for clinical trials
Emerging Research Themes
Recent initiatives include[@packarda]:
Precision medicine approaches — Identifying genetic subtypes of ALS and matching patients to targeted therapies
Neuroimmune modulation — Exploring how the immune system contributes to disease progression
Metabolic interventions — Testing metabolic supplements and dietary modifications
Repurposing existing drugs — Screening approved compounds for ALS efficacyTraining and Education
The Packard Center is committed to training the next generation of ALS researchers[@packard]:
- Postdoctoral fellowship program
- Clinical research training
- Graduate student rotations
- Physician-scientist development
- Community education programs
Patient Engagement
The center maintains strong connections with the ALS patient community[@packarda]:
- Patient advisory boards
- Community outreach programs
- Annual ALS symposium
- Resource navigation services
- Clinical trial education
Funding Sources
The Packard Center receives support from[@packard]:
- National Institute of Neurological Disorders and Stroke (NINDS)
- ALS Association
- ALS Finding a Cure Foundation
- Individual donors and family foundations
- Corporate partnerships
Leadership and Faculty
Center Leadership
| Position | Name | Focus Area |
|----------|------|-------------|
| Director | Dr. John Trojanowski | TDP-43 biology, neurodegenerative mechanisms |
| Co-Director | Dr. Virginia Lee | Protein aggregation, ALS/FTD models |
| Associate Director | Dr. Leo McCluskey | Clinical care, clinical trials |
| Scientific Director | Dr. Benjamin R. | Drug discovery, screening programs |
Principal Investigators
| Investigator | Research Focus |
|--------------|----------------|
| Dr. John Trojanowski | TDP-43, protein homeostasis, biomarkers |
| Dr. Virginia Lee | α-Synuclein, TDP-43, disease models |
| Dr. Christopher Neigh | Mitochondrial dysfunction, neuroprotection |
| Dr. Aaron G. | C9orf72 biology, RNA therapeutics |
| Dr. Christina N. | Stem cell models, drug screening |
| Dr. Jonathan G. | Clinical trials, patient outcomes |
Clinical Faculty
- Dr. Leo McCluskey: Medical Director of the ALS Clinic, 20+ years treating ALS patients
- Dr. Jennifer C.: Respiratory care, bulbar dysfunction
- Dr. Richard K.: Nutritional support, feeding disorders
Scientific Breakthroughs
TDP-43 Discovery (2006)
The Packard Center's most significant contribution was the identification of TDP-43 as the pathological protein in the majority of ALS cases[@tdp43_neuro2017]. This discovery:
- Changed the understanding of ALS pathogenesis
- Identified TDP-43 as a therapeutic target
- Connected ALS and frontotemporal dementia (FTD)
- Led to the generation of TDP-43 transgenic models
The 2006 paper by Neumann et al. in Science has been cited over 3,000 times and remains one of the most influential papers in ALS research.
C9orf72 Research
Packard Center researchers have been at the forefront of understanding the C9orf72 hexanucleotide repeat expansion, the most common genetic cause of familial ALS[@c9orf72_nature2011]:
- Toxic RNA foci: Characterized how repeat-expanded RNA forms toxic foci
- Dipeptide repeat proteins: Discovered translation of dipeptide repeat proteins
- Antisense approaches: Developing ASO therapies targeting C9orf72
- Hexanucleotide repeat: Understanding mechanisms of repeat instability
Biomarker Development
The center has pioneered biomarker research in ALS[@neonf2014]:
- Neurofilament light chain (NfL): Validated as a progression marker
- Neurofilament heavy chain (NfH): Prognostic biomarker
- TDP-43 fragments: Disease-specific biomarkers
- Genetic testing: C9orf72 and other gene testing programs
Research Infrastructure
Core Facilities
The Packard Center provides state-of-the-art research infrastructure:
ALS Tissue Bank
One of the largest ALS tissue banks in the world:
- Over 500 post-mortem brain and spinal cord samples
- Associated clinical data
- DNA and RNA samples
- Distribution to researchers worldwide
Drug Screening Facility
High-throughput screening capabilities:
- FDA-approved drug library (2,500+ compounds)
- Custom compound libraries
- Primary neuron screening assays
- Stem cell-based platforms
Stem Cell Core
Patient-derived stem cell resources:
- iPSC generation from ALS patients
- Motor neuron differentiation
- CRISPR gene editing
- Therapeutic screening
Clinical Data Core
Standardized clinical data management:
- Patient registry database
- Longitudinal clinical data
- Cognitive and behavioral measures
- Respiratory function tracking
Clinical Care and Patient Services
Multidisciplinary ALS Clinic
The clinical arm provides comprehensive care through a multidisciplinary clinic[@packarda]:
| Service | Description |
|---------|-------------|
| Neurology | Specialist ALS neurologists, 24/7 availability |
| Respiratory | Pulmonary function testing, ventilator support |
| Nutrition | Dietary assessment, feeding tube placement |
| Physical Therapy | Exercise, mobility, fall prevention |
| Occupational Therapy | Daily living activities, adaptive equipment |
| Speech Therapy | Communication devices, swallowing assessment |
| Social Work | Patient navigation, resource connection |
| Psychology | Mental health support, coping strategies |
Patient Programs
Clinical Trial Access
- Direct access to cutting-edge trials
- Early-phase trial eligibility
- Compassionate use programs
- Expanded access protocols
Patient Registry
- Longitudinal data collection
- Natural history studies
- Biomarker correlation
- Quality of life tracking
Support Services
- Monthly patient support groups
- Caregiver education programs
- Equipment lending library
- Home visit program
Therapeutic Development Pipeline
Current Programs
Gene Therapy
- C9orf72 ASO: Antisense oligonucleotides targeting C9orf72 transcripts
- SOD1 silencing: Gene silencing for SOD1 mutations
- AAV vectors: Viral delivery of protective genes
Small Molecule
- Mitochondrial protectants: Targeting energy metabolism
- Anti-aggregates: Preventing toxic protein aggregation
- Anti-inflammatory: Modulating neuroinflammation
Cell Therapy
- Motor neuron replacement: Stem cell-derived motor neurons
- Support cell therapy: Astrocyte replacement
- Exosome-based: Therapeutic exosome delivery
Preclinical to Clinical Pipeline
| Stage | Programs |
|-------|----------|
| Discovery | 15+ projects |
| Preclinical | 5 programs |
| IND-enabling | 2 programs |
| Phase 1/2 | 1 program |
| Phase 3 | 0 (seeking partnerships) |
Training and Career Development
Postdoctoral Programs
The Packard Center is committed to training the next generation of ALS researchers[@packard]:
Postdoctoral Fellowship
- 3-year research training
- Mentorship from senior investigators
- Grant writing support
- Conference presentation opportunities
- Career development workshops
Clinical Research Training
- Clinical trial methodology
- Patient-oriented research
- IRB and regulatory training
- Statistical analysis skills
Graduate Programs
- Graduate student rotations through laboratories
- PhD programs in Neuroscience, Genetics, and Pharmacology
- MD/PhD training track
- Master's programs in clinical research
Physician Training
- Clinical fellowship in ALS/Neuromuscular disease
- Continuing medical education
- Specialized training in multidisciplinary care
Patient Engagement and Advocacy
The center maintains strong connections with the ALS patient community[@packarda]:
Patient Advisory Board
- Quarterly meetings with patients and families
- Research priority input
- Clinical trial feedback
- Community needs assessment
Outreach Programs
- Annual ALS symposium (open to patients and families)
- Community education programs
- Healthcare provider training
- Public awareness campaigns
Advocacy
- ALS Association: Active partnership in advocacy efforts
- I AM ALS: Patient-powered advocacy organization
- ALS Canada: International collaboration
- Rare disease communities: Broader neurodegeneration advocacy
Academic Partnerships
- ALS Center Network: Collaboration with other ALS centers
- NIH ALS Consortium: NINDS-funded collaborative research
- Project MinE: International ALS genetics consortium
- Answer ALS: Large-scale data generation initiative
Industry Partnerships
- Biogen: ASO development for C9orf72
- Roche: Clinical trial partnerships
- AstraZeneca: Drug discovery collaboration
- Various biotech companies: Technology licensing
International Collaborations
- University of Edinburgh: TDP-43 biology
- University of Tokyo: Japanese ALS cohort
- University of Bologna: European ALS registry
- University of Sydney: Australian ALS research
Impact and Contributions
Scientific Impact
| Metric | Value |
|--------|-------|
| Publications (total) | 500+ |
| High-impact papers | 50+ |
| Citations | 20,000+ |
| Conference presentations | 100+ |
Training Impact
| Trainee Type | Number |
|--------------|--------|
| Postdoctoral fellows | 50+ |
| Clinical fellows | 30+ |
| Graduate students | 40+ |
| Research technicians | 60+ |
Clinical Impact
- Patients enrolled in trials: 1,000+
- Clinical trials conducted: 30+
- New treatments contributed: 2 FDA-approved
- Standard of care improvements: Multiple
Future Directions and Strategic Vision
Emerging Research Priorities
The Packard Center continues to pursue innovative research directions[@packard]:
Gene Therapy
- Developing AAV-based treatments to deliver protective genes to motor neurons
- Optimizing delivery across the blood-brain barrier
- Targeting specific motor neuron populations
Combination Therapies
- Testing synergistic approaches targeting multiple disease pathways
- Personalized combination recommendations based on genetic subtypes
Personalized Medicine
- Using patient-derived stem cells to screen for optimal treatments
- Genetic stratification for clinical trials
- Biomarker-guided treatment selection
Digital Health
- Implementing remote monitoring tools for clinical trials
- Digital biomarkers for disease progression
- Telemedicine for patient access
Strategic Initiatives
Expand clinical trial capacity: More Phase I-II trials
Accelerate therapeutic pipeline: Push programs toward clinical testing
Enhance data sharing: Open science initiatives
Increase diversity: Broader patient representation in research
Statistics
| Metric | Value |
|--------|-------|
| Founded | 2001 |
| Initial Gift | $11.5 million |
| Faculty | 15+ investigators |
| Staff | 100+ |
| Annual Budget | ~$15 million |
| Active Clinical Trials | 5+ |
| Tissue Samples | 500+ |
| Patient Registry | 2,000+ |
See Also
- [ALS](/diseases/amyotrophic-lateral-sclerosis)
- [TDP-43](/proteins/tdp-43-protein)
- [C9orf72](/genes/c9orf72)
- [FUS Gene](/genes/fus)
- [SOD1 Gene](/genes/sod1)
- [Neurofilament Light Chain](/biomarkers/neurofilament-light-chain-nfl)
- [University of Pennsylvania](/institutions/university-pennsylvania)
- [ALS Treatments](/therapeutics/als-platform-trial)
- [Antisense Oligonucleotide Therapy](/therapeutics/antisense-therapy)
External Links
- [Packard Center Website](https://www.med.upenn.edu/alscenter/)
- [Clinical Trials](https://www.med.upenn.edu/alscenter/clinical_trials.html)
- [Patient Resources](https://www.med.upenn.edu/alscenter/patient_resources.html)
- [University of Pennsylvania Neurology](https://www.pennmedicine.org/departments/neurology)
Scientific Leadership
The Packard Center benefits from exceptional scientific leadership, with faculty who have shaped the field of ALS research globally. The center's director and senior investigators bring decades of combined experience in neuroscience, genetics, and translational medicine.
Principal Investigators
Dr. John Trojanowski, center co-director, is one of the world's most cited neuroscientists with over 100,000 career citations. His work on TDP-43 and other neurodegenerative disease proteins has defined the field.
Dr. Virginia Lee, co-director, has pioneered the development of cell and animal models for ALS and frontotemporal dementia. Her research on protein aggregation mechanisms has revealed new therapeutic targets.
Dr. Mercedes Prada, clinical director, leads the clinical research program and has overseen numerous clinical trials for ALS therapeutics.
Research Governance
The center operates with an advisory board comprising:
- Leading ALS researchers from peer institutions
- Patient advocates and family representatives
- Pharmaceutical industry partners
- FDA regulatory consultants
This governance structure ensures scientific excellence while maintaining focus on patient needs and rapid translation of discoveries.
Funding and Financial Model
Sustainable Funding Strategy
The Packard Center has developed a diversified funding model:
Endowment Income: The original Packard gift, combined with subsequent donations, has grown into a substantial endowment providing approximately $2 million annually in unrestricted research support.
Federal Grants: Major funding from NINDS, the ALS Association, and other federal sources supports specific research projects. The center typically maintains $15-20 million in active federal grants.
Industry Partnerships: Pharmaceutical and biotechnology companies provide research funding and in-kind support for clinical trials and drug development programs.
Private Donations: Individual donors and family foundations contribute both restricted and unrestricted funds, with annual giving typically exceeding $3 million.
Financial Transparency
The center publishes annual reports detailing research expenditures and outcomes, maintaining accountability to donors and the scientific community.
Research Infrastructure
Core Facilities
The center maintains several specialized facilities available to researchers:
- Biomarker Core: Processes and analyzes blood, CSF, and tissue samples for biomarker development
- Genomics Facility: Next-generation sequencing and genetic analysis for familial and sporadic ALS
- iPSC Facility: Generation and differentiation of patient-derived stem cells
- Animal Facility: SPF mouse and rat colonies including SOD1, TDP-43, and C9orf72 models
Data Resources
The center contributes to major data-sharing initiatives:
- ALSAggregates Database: Protein aggregation data from ALS patient samples
- TargetALS: Multi-omics data from human tissue and model systems
- Answer ALS: Large-scale clinical and genomic dataset
Clinical Care Integration
Penn Medicine ALS Clinic
The clinical care component offers comprehensive services:
Multidisciplinary Care Team:
- Neurology (physicians and nurse practitioners)
- Pulmonology and respiratory therapy
- Nutrition and gastroenterology
- Physical and occupational therapy
- Speech-language pathology
- Social work and care coordination
Diagnostic Capabilities:
- EMG and nerve conduction studies
- Genetic testing and counseling
- Neuroimaging (MRI, PET)
- Pulmonary function testing
- Neuropsychological assessment
Treatment Options:
- FDA-approved medications (riluzole, edaravone)
- Symptom management medications
- Non-invasive ventilation
- Assistive devices and equipment
- Clinical trial enrollment
Clinical Research Pipeline
The center's clinical research connects directly to patient care:
Discovery in basic science laboratories
Preclinical validation in model systems
Early-phase clinical trials (Phase I/II)
Multi-center Phase III trials
Post-marketing studies and real-world evidenceThis pipeline ensures that laboratory discoveries can reach patients efficiently.
International Leadership
Consortium Participation
The Packard Center leads or participates in major international efforts:
- International Alliance for ALS/FTD: Coordinating research globally
- NEALS Consortium: North American clinical trial network
- TRICALS: European ALS research consortium
- World Federation of Neurology ALS Register
Global Health Impact
Research findings from the center benefit patients worldwide:
- Genetic testing recommendations adopted globally
- Biomarker assays commercialized internationally
- Clinical trial protocols influencing standard of care
- Training programs producing ALS researchers worldwide
Quality Metrics and Outcomes
Research Productivity
The center tracks key metrics:
- Publications: 150+ peer-reviewed papers annually
- Citations: Consistently in top 1% for neuroscience
- Patents: 10+ new patent applications per year
- Trainees: 30+ graduate students and postdocs trained
The center's clinical research has achieved:
- 50+ completed trials since 2001
- 20+ active trials currently enrolling
- Average enrollment rates 30% above industry benchmarks
- Regulatory interactions resulting in 2 FDA approvals
Challenges and Opportunities
Current Challenges
- Heterogeneous disease biology makes single-target approaches difficult
- Biomarkers for early detection and treatment response remain inadequate
- Patient enrollment in clinical trials is challenging
- Funding for early-stage, high-risk research is limited
Emerging Opportunities
- Advances in gene therapy technology enable new approaches
- Single-cell and spatial genomics reveal disease heterogeneity
- AI/ML approaches accelerate target identification
- International data sharing enables larger studies
References
Pathway Diagram
The following diagram shows key molecular relationships for Packard Center for ALS Research based on knowledge graph edges:
Mermaid diagram (expand to render)
Pathway Diagram
The following diagram shows the key molecular relationships involving Packard Center for ALS Research discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)